Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NYMX Nymox Pharmaceutical (NYMX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Nymox Pharmaceutical Stock (NASDAQ:NYMX) 30 days 90 days 365 days Advanced Chart Ad Darwin2025: Digital Asset Insights You Need to KnowCryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.Get your guide today! Get Nymox Pharmaceutical alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.19▼$0.4752-Week Range N/AVolume932,700 shsAverage Volume94,622 shsMarket Capitalization$18.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.Read More… 2025: Digital Asset Insights You Need to Know (Ad)Cryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.Get your guide today! Receive NYMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address NYMX Stock News HeadlinesNymox Announces Filing of Annual ReportAugust 31, 2024 | markets.businessinsider.comNymox Annual ReportJuly 21, 2024 | finance.yahoo.comDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.November 23, 2024 | DTI (Ad)Nymox December 27 Message to ShareholdersDecember 27, 2023 | markets.businessinsider.comNymox Pharmaceutical Corporation: Nymox December 27 Message to ShareholdersDecember 27, 2023 | finanznachrichten.deNymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and OthersNovember 30, 2023 | finance.yahoo.comNymox Pharmaceutical Corporation: $250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California CourtNovember 22, 2023 | finanznachrichten.de$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California CourtNovember 21, 2023 | markets.businessinsider.comSee More Headlines NYMX Stock Analysis - Frequently Asked Questions How were Nymox Pharmaceutical's earnings last quarter? Nymox Pharmaceutical Co. (NASDAQ:NYMX) announced its quarterly earnings data on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. The biopharmaceutical company earned $0.08 million during the quarter. What other stocks do shareholders of Nymox Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Biocept (BIOC), TherapeuticsMD (TXMD) and CTI BioPharma (CTIC). Company Calendar Last Earnings11/14/2014Today11/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:NYMX CUSIPN/A CIK1018735 Webwww.nymox.com Phone(800) 936-9669Fax514-332-2227Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,589.50% Return on Assets-117.25% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / BookN/AMiscellaneous Outstanding Shares90,510,000Free Float41,637,000Market Cap$18.10 million OptionableOptionable Beta0.64 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:NYMX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nymox Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nymox Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
